News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nutra Pharma Corp. (NPHC) Announces Infrastructure Improvements To Handle Increased Sales



7/24/2014 10:08:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CORAL SPRINGS, Fla., July 24, 2014 (GLOBE NEWSWIRE) -- Nutra Pharma Corp. (OTCPink:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they are in the process of completing critical capital improvements to their warehouse and fulfillment center in order to meet increased demand and shipments of their over-the-counter (OTC) pain reliever, Nyloxin®. These improvements include: new rack systems throughout the facility, the purchase of a forklift, new management software as well as hiring additional staff.

"Sales of Nyloxin have been steadily increasing over the past few months," said Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "With the additional orders, we've had to make some capital investments in our infrastructure to keep up with demand," he continued. "The improvements to the fulfillment center will help improve deliveries and streamline the shipping process. It will also help us gear up for the launch of Pet Pain-Away in the fall," he concluded.

Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin® is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

Pet Pain-Away is a new product primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in companion animals. Specialized proteins in Pet Pain-Away block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin®. For additional information about Nutra Pharma, visit:

http://www.NutraPharma.com or

http://www.Nyloxin.com.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's infrastructure improvements should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

CONTACT: Nutra Pharma Corp. Nina Goldstein 877-895-5647 IR@nutrapharma.com

Nutra Pharma Corp. logo


Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES